Search

Your search keyword '"Mons, F."' showing total 35 results
Start Over Author "Mons, F."
35 results on '"Mons, F."'

2. L’enveloppement, l’habillage et les tissus en contact avec l’enfant en néonatologie

Author

Allen, A., Audeoud, F., Bouvard, C., Brandicourt, A., Caeymaex, L., Duboz, M.A., Evrard, A., Fichtner, C., Fischer-Fumeaux, C., Girard, L., Gonnaud, F., Hüppi, P., Knezovic, N., Kuhn, P., Laprugne-Garcia, E., Legouais, S., Mons, F., Muller, J.-B., Picaud, J.-C., Pierrat, V., Pladys, P., Reynaud, A., Renesme, L., Rideau, A., Sizun, J., Souet, G., Thiriez, G., Tourneux, P., Touzet, M., Truffert, P., Tscherning, C., Zaoui, C., Zana-Taieb, E., Zores-Koenig, C., Berne Audéoud, F., and Lenglemetz, S.L.

Published
2023
Full Text
View/download PDF

3. Accès et rôle des parents en néonatalogie en période d’épidémie COVID-19 — Propositions du GREEN de la SFN

Author

Allen, A., Audeoud, F., Bouvard, C., Brandicourt, A., Caeymaex, L., Duboz, M.A., Evrard, A., Fichtner, C., Fischer-Fumeaux, C., Girard, L., Gonnaud, F., Hüppi, P., Knezovic, N., Kuhn, P., Laprugne-Garcia, E., Legouais, S., Mons, F., Muller, J.-B., Picaud, J.-C., Pierrat, V., Pladys, P., Reynaud, A., Renesme, L., Rideau, A., Sizun, J., Souet, G., Thiriez, G., Tourneux, P., Touzet, M., Truffert, P., Tscherning, C., Zaoui, C., Zana-Taieb, E., and Zores, C.

Published
2020
Full Text
View/download PDF

4. La famille dans les unités de médecine néonatale

Author

Allen, A., Audeoud, F., Bouvard, C., Brandicourt, A., Casper, C., Cayemaex, L., Denoual, H., Duboz, M.A., Evrard, A., Fichtner, C., Fischer-Fumeaux, C., Girard, L., Gonnaud, F., Haumont, D., Hüppi, P., Knezovic, N., Kuhn, P., Laprugne-Garcia, E., Legouais, S., Mons, F., Pelofy, V., Picaud, J.-C., Pierrat, V., Renaud, A., Renesme, L., Sizun, J., Souet, G., Thiriez, G., Tourneux, P., Touzet, M., Truffert, P., Zaoui, C., Zana-Taieb, E., Zores, C., and Reynaud, A.

Published
2018
Full Text
View/download PDF

5. Le portage des nouveau-nés en peau à peau

Author

Allen, A., Audeoud, F., Bouvard, C., Brandicourt, A., Casper, C., Cayemaex, L., Denoual, H., Duboz, M.A., Evrard, A., Fichtner, C., Fischer-Fumeaux, C., Girard, L., Gonnaud, F., Haumont, D., Hüppi, P., Knezovic, N., Kuhn, P., Laprugne-Garcia, E., Legouais, S., Mons, F., Pelofy, V., Picaud, J.-C., Pierrat, V., Renaud, A., Renesme, L., Sizun, J., Souet, G., Thiriez, G., Tourneux, P., Touzet, M., Truffert, P., Zaoui, C., Zana-Taieb, E., Zores, C., and Zaoui-Grattepanche, C.

Published
2018
Full Text
View/download PDF

6. Recommendation for hygiene and topical in neonatology from the French Neonatal Society

Author

Renesme, Laurent, Allen, A., Audeoud, F., Bouvard, C., Brandicourt, A., Casper, C., Cayemaex, L., Denoual, H., Duboz, M. A., Evrard, A., Fichtner, C., Fischer-Fumeaux, C. J., Girard, L., Gonnaud, F., Haumont, D., Hüppi, P., Knezovic, N., Laprugne-Garcia, E., Legouais, S., Mons, F., Pelofy, V., Picaud, J. C., Pierrat, V., Pladys, P., Reynaud, A., Souet, G., Thiriez, G., Tourneux, P., Touzet, M., Truffert, P., Zaoui, C., Zana-Taieb, E., Zores, C., Sizun, J., and Kuhn, P.

Published
2019
Full Text
View/download PDF

7. Perception des parents de leur participation aux soins de leur enfant dans les unités de néonatologie en France

Author

Allen, A., Brandicourt, A., Duboz, M.-A., Fichtner, C., Girard, L., Gonnaud, F., Haumont, D., Hüppi, P., Isaia, S., Knezovic, N., Legouais, S., Mons, F., Pelofy, V., Picaud, J.-C., Pierrat, V., Renesme, L., Sizun, J., Souet, G., Thiriez, G., Truffert, P., Zaoui, C., Zores, C., Casper, C., Caeymaex, L., Dicky, O., Akrich, M., Reynaud, A., Bouvard, C., Evrard, A., and Kuhn, P.

Published
2016
Full Text
View/download PDF

8. L’enveloppement, l’habillage et les tissus en contact avec l’enfant en néonatologie

Author

Berne Audéoud, F., primary, Lenglemetz, S.L., additional, Touzet, M., additional, Thiriez, G., additional, Allen, A., additional, Audeoud, F., additional, Bouvard, C., additional, Brandicourt, A., additional, Caeymaex, L., additional, Duboz, M.A., additional, Evrard, A., additional, Fichtner, C., additional, Fischer-Fumeaux, C., additional, Girard, L., additional, Gonnaud, F., additional, Hüppi, P., additional, Knezovic, N., additional, Kuhn, P., additional, Laprugne-Garcia, E., additional, Legouais, S., additional, Mons, F., additional, Muller, J.-B., additional, Picaud, J.-C., additional, Pierrat, V., additional, Pladys, P., additional, Reynaud, A., additional, Renesme, L., additional, Rideau, A., additional, Sizun, J., additional, Souet, G., additional, Tourneux, P., additional, Truffert, P., additional, Tscherning, C., additional, Zaoui, C., additional, Zana-Taieb, E., additional, and Zores-Koenig, C., additional

Published
2023
Full Text
View/download PDF

9. Antibiotic prophylaxis in preterm premature rupture of membranes at 24–31 weeks’ gestation: Perinatal and 2‐year outcomes in the EPIPAGE‐2 cohort

Author

Lorthe, Elsa, Letouzey, Mathilde, Torchin, Héloïse, Foix L'Helias, Laurence, Gras‐le Guen, Christèle, Benhammou, Valérie, Boileau, Pascal, Charlier, Caroline, Kayem, Gilles, Ancel, Pierre‐yves, Arnaud, Catherine, Blanc, Julie, Debillon, Thierry, Delorme, Pierre, D’ercole, Claude, Desplanches, Thomas, Diguisto, Caroline, Gascoin, Géraldine, Gire, Catherine, Goffinet, François, Langer, Bruno, Maisonneuve, Emeline, Marret, Stéphane, Monier, Isabelle, Morgan, Andrei, Rozé, Jean‐christophe, Schmitz, Thomas, Sentilhes, Loïc, Subtil, Damien, Tosello, Barthélémy, Vayssière, Christophe, Winer, Norbert, Zeitlin, Jennifer, Astruc, D, Kuhn, P, Matis, J, Ramousset, C, Hernandorena, X, Chabanier, P, Joly‐pedespan, L, Costedoat, Mj, Leguen, A, Lecomte, B, Lemery, D, Vendittelli, F, Beucher, G, Dreyfus, M, Guillois, B, Toure, Y, Burguet, A, Couvreur, S, Gouyon, Jb, Sagot, P, Colas, N, Sizun, J, Beuchée, A, Pladys, P, Rouget, F, Dupuy, Rp, Soupre, D, Charlot, F, Roudaut, S, Favreau, A, Saliba, E, Reboul, L, Bednarek, N, Morville, P, Verrière, V, Thiriez, G, Balamou, C, Marpeau, L, Barbier, C, Durrmeyer, X, Granier, M, Ayoubi, M, Baud, O, Carbonne, B, Jarreau, Ph, Mitanchez, D, Duffaut, C, Cornu, L, Moras, R, Boulot, P, Cambonie, G, Daudé, H, Badessi, A, Tsaoussis, N, Bédu, A, Mons, F, Bahans, C, Binet, Mh, Fresson, J, Hascoët, Jm, Milton, A, Morel, O, Vieux, R, Hilpert, L, Alberge, C, Baron, M, Charkaluk, Ml, Pierrat, V, Truffert, P, Akowanou, S, Simeoni, U, Bongain, A, Deschamps, M, Branger, B, Rouger, V, Dupont, C, Gondry, Jean, Krim, G, Baby, B, Debeir, M, Claris, O, Picaud, Jc, Rubio‐gurung, S, Cans, C, Ego, A, Patural, H, Rannaud, A, Janky, E, Poulichet, A, Rosenthal, Jm, Coliné, E, Favre, A, Joly, N, Châlons, S, Pignol, J, Laurence, Pl, Robillard, Py, Samperiz, S, Ramful, D, Blondel, B, Bonet, M, Brinis, A, Coquelin, A, Durox, M, Kaminski, M, Khemache, K, Khoshnood, B, Lebeaux, C, Marchand‐martin, L, Rousseau, J, Saurel‐cubizolles, Mj, Tran, D, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris], Assistance Publique - Hôpitaux de Paris, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service Epidémiologie clinique et santé publique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Unité de biostatistiques [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Médecine Néonatale et Réanimation Pédiatrique CHU Grenoble, CHU Grenoble, Service de gynécologie-obstétrique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Service de Gynécologie Obstétrique, Médecine Foetale et Stérilité Conjugale - Chirurgie Gynécologie et Oncologique [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Néonatologie, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Recherches épidémiologiques en santé périnatale et santé des femmes, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Groupe de Recherche sur l'Analyse Multimodale de la Fonction Cérébrale - UMR INSERM_S 1105 (GRAMFC), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Amiens-Picardie, Funding information:This work was partly supported by a postdoctoral grant from the Fondation des Treilles to EL. EPIPAGE-2 was funded by the French Institute of Public Health Research (IRESP TGIR 2009-01 programme)/Institute of Public Health and its partners: the French Health Ministry, the National Institute of Health and Medical Research (INSERM), the National Institute of Cancer, and the National Solidarity Fund for Autonomy (CNSA), the National Research Agency through the French EQUIPEX programme of investments for the future (grant number ANR-11-EQPX-0038), and the PREMUP Foundation. Additional funding was obtained from Fondation pour la Recherche Medicale (grant number SPF 20160936356) and Fondation de France (grant numbers 00050329, Grand Prix R18202KK]). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., ANR-11-EQPX-0038,RE-CO-NAI,Plateforme de REcherche sur les COhortes d'enfants suivis depuis la NAIssance(2011), Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Education, Formation, Travail, Savoirs (EFTS), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-École Nationale Supérieure de Formation de l'Enseignement Agricole de Toulouse-Auzeville (ENSFEA), École Nationale Supérieure de Formation de l'Enseignement Agricole de Toulouse-Auzeville (ENSFEA), Centre Hospitalier Universitaire [Grenoble] (CHU), Modélisation et Évaluation des données complexes en Santé Publique (TIMC-MESP), Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), CHU Dijon, Hôpital Nord [CHU - APHM], Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Department of Obstetrics and Gynecology, Les Hôpitaux Universitaires de Strasbourg (HUS), EPIPAGE-2 Study Group, and Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Fetal Membranes, Premature Rupture, obstetric intervention, [SDV]Life Sciences [q-bio], Gestational Age, antenatal management, Cohort Studies, Pregnancy, Escherichia coli, Humans, Prospective Studies, latency, amoxicillin, neurodevelopment, macrolides, prematurity, Infant, Newborn, Pregnancy Outcome, Obstetrics and Gynecology, Infant, prophylactic antibiotics, Antibiotic Prophylaxis, Anti-Bacterial Agents, perinatal outcome, cephalosporins, Premature Birth, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neonatal Sepsis, Infant, Premature
Abstract

To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age.Prospective, nationwide, population-based EPIPAGE-2 cohort study of preterm infants.France, 2011.We included 492 women with a singleton pregnancy and a diagnosis of preterm premature rupture of membranes at 24-31 weeks. Exclusion criteria were contraindication to expectant management or indication for antibiotic therapy other than preterm premature rupture of membranes. Antibiotic prophylaxis was categorised as amoxicillin (n = 345), macrolide (n = 30), third-generation cephalosporin (n = 45) or any combinations covering Streptococcus agalactiae and90% of Escherichia coli (n = 72), initiated within 24 hours after preterm premature rupture of membranes.Population-averaged robust Poisson models.Survival at discharge without severe neonatal morbidity, 2-year neurodevelopment.With amoxicillin, macrolide, third-generation cephalosporin and combinations, 78.5%, 83.9%, 93.6% and 86.0% of neonates were discharged alive without severe morbidity. The administration of third-generation cephalosporin or any E. coli-targeting combinations was associated with improved survival without severe morbidity (adjusted risk ratio 1.25 [95% confidence interval 1.08-1.45] and 1.10 [95 % confidence interval 1.01-1.20], respectively) compared with amoxicillin. We evidenced no increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen.In preterm premature rupture of membranes at 24-31 weeks, antibiotic prophylaxis based on third-generation cephalosporin may be associated with improved survival without severe neonatal morbidity when compared with amoxicillin, with no evidence of increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen.Antibiotic prophylaxis after PPROM at 24-31 weeks: 3rd-generation cephalosporins associated with improved neonatal outcomes.

Published
2022
Full Text
View/download PDF

10. Cohort Profile: the Etude Epidémiologique sur les Petits Ages Gestationnels-2 (EPIPAGE-2) preterm birth cohort

Author

Lorthe, Elsa, Benhammou, Valérie, Marchand-Martin, Laetitia, Pierrat, Véronique, Lebeaux, Cécile, Durox, Mélanie, Goffinet, François, Kaminski, Monique, Ancel, Pierre-Yves, Astruc, D, Kuhn, P, Langer, B, Matis, J, Ramousset, C, Hernandorena, X, Chabanier, P, Joly-Pedespan, L, Rebola, M, Costedoat, M, Leguen, A, Martin, C, Lecomte, B, Lemery, D, Vendittelli, F, Rochette, E, Beucher, G, Dreyfus, M, Guillois, B, Toure, Y, Rots, D, Burguet, A, Couvreur, S, Gouyon, J, Sagot, P, Colas, N, Franzin, A, Sizun, J, Beuchée, A, Pladys, P, Rouget, F, Dupuy, R, Soupre, D, Charlot, F, Roudaut, S, Favreau, A, Saliba, E, Reboul, L, Aoustin, E, Bednarek, N, Morville, P, Verrière, V, THIRIEZ, G, Balamou, C, Ratajczak, C, Marpeau, L, Marret, S, Barbier, C, Mestre, N, Kayem, G, Durrmeyer, X, Granier, M, Lapillonne, A, Ayoubi, M, Baud, O, Carbonne, B, Foix L’Hélias, L, Jarreau, P, Mitanchez, D, Boileau, P, Duffaut, C, Cornu, L, Moras, R, Salomon, D, Medjahed, S, Ahmed, K, Boulot, P, Cambonie, G, Daudé, H, Badessi, A, Tsaoussis, N, Poujol, M, Bédu, A, Mons, F, Bahans, C, Binet, M, Fresson, J, Hascoët, J, Milton, A, Morel, O, Vieux, R, Hilpert, L, Alberge, C, Arnaud, C, Vayssière, C, Baron, M, Charkaluk, M, Subtil, D, Truffert, P, Akowanou, S, Roche, D, Thibaut, M, D’Ercole, C, Gire, C, Simeoni, U, Bongain, A, DESCHAMPS, M, Zahed, M, Branger, B, Rozé, J, Winer, N, Gascoin, G, Sentilhes, L, Rouger, V, Dupont, C, Martin, H, Gondry, J, Krim, G, Baby, B, Popov, I, Debeir, M, Claris, O, Picaud, J, Rubio-Gurung, S, Cans, C, Ego, A, Debillon, T, Patural, H, Rannaud, A, Janky, E, Poulichet, A, Rosenthal, J, Coliné, E, Cabrera, C, Favre, A, Joly, N, Stouvenel, A, Châlons, S, Pignol, J, Laurence, P, Lochelongue, V, Robillard, P, Samperiz, S, Ramful, D, Asadullah, H, Blondel, B, Bonet, M, Brinis, A, Coquelin, A, Delormel, V, Esmiol, S, Fériaud, M, Foix-L’Hélias, L, Khemache, K, Khoshnood, B, Onestas, L, Quere, M, Rousseau, J, Rtimi, A, Saurel-Cubizolles, M, Tran, D, Sylla, D, Vasante-Annamale, L, Zeitlin, J, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), CHU Estaing [Clermont-Ferrand], and CHU Clermont-Ferrand

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021
Full Text
View/download PDF

13. Accès et rôle des parents en néonatalogie en période d’épidémie COVID-19 — Propositions du GREEN de la SFN

Author

Kuhn, P., primary, Sizun, J., additional, Tscherning, C., additional, Allen, A., additional, Audeoud, F., additional, Bouvard, C., additional, Brandicourt, A., additional, Caeymaex, L., additional, Duboz, M.A., additional, Evrard, A., additional, Fichtner, C., additional, Fischer-Fumeaux, C., additional, Girard, L., additional, Gonnaud, F., additional, Hüppi, P., additional, Knezovic, N., additional, Kuhn, P., additional, Laprugne-Garcia, E., additional, Legouais, S., additional, Mons, F., additional, Muller, J.-B., additional, Picaud, J.-C., additional, Pierrat, V., additional, Pladys, P., additional, Reynaud, A., additional, Renesme, L., additional, Rideau, A., additional, Souet, G., additional, Thiriez, G., additional, Tourneux, P., additional, Touzet, M., additional, Truffert, P., additional, Zaoui, C., additional, Zana-Taieb, E., additional, and Zores, C., additional

Published
2020
Full Text
View/download PDF

16. La famille dans les unités de médecine néonatale

Author

Casper, C., primary, Fichtner, C., additional, Gonnaud, F., additional, Knezovic, N., additional, Reynaud, A., additional, Kuhn, P., additional, Sizun, J., additional, Allen, A., additional, Audeoud, F., additional, Bouvard, C., additional, Brandicourt, A., additional, Casper, C., additional, Cayemaex, L., additional, Denoual, H., additional, Duboz, M.A., additional, Evrard, A., additional, Fischer-Fumeaux, C., additional, Girard, L., additional, Haumont, D., additional, Hüppi, P., additional, Laprugne-Garcia, E., additional, Legouais, S., additional, Mons, F., additional, Pelofy, V., additional, Picaud, J.-C., additional, Pierrat, V., additional, Renaud, A., additional, Renesme, L., additional, Souet, G., additional, Thiriez, G., additional, Tourneux, P., additional, Touzet, M., additional, Truffert, P., additional, Zaoui, C., additional, Zana-Taieb, E., additional, and Zores, C., additional

Published
2018
Full Text
View/download PDF

17. Le portage des nouveau-nés en peau à peau

Author

Zaoui-Grattepanche, C., primary, Kuhn, P., additional, Pierrat, V., additional, Allen, A., additional, Audeoud, F., additional, Bouvard, C., additional, Brandicourt, A., additional, Casper, C., additional, Cayemaex, L., additional, Denoual, H., additional, Duboz, M.A., additional, Evrard, A., additional, Fichtner, C., additional, Fischer-Fumeaux, C., additional, Girard, L., additional, Gonnaud, F., additional, Haumont, D., additional, Hüppi, P., additional, Knezovic, N., additional, Laprugne-Garcia, E., additional, Legouais, S., additional, Mons, F., additional, Pelofy, V., additional, Picaud, J.-C., additional, Renaud, A., additional, Renesme, L., additional, Sizun, J., additional, Souet, G., additional, Thiriez, G., additional, Tourneux, P., additional, Touzet, M., additional, Truffert, P., additional, Zaoui, C., additional, Zana-Taieb, E., additional, and Zores, C., additional

Published
2018
Full Text
View/download PDF

19. Perception des parents de leur participation aux soins de leur enfant dans les unités de néonatologie en France

Author

Casper, C., primary, Caeymaex, L., additional, Dicky, O., additional, Akrich, M., additional, Reynaud, A., additional, Bouvard, C., additional, Evrard, A., additional, Kuhn, P., additional, Allen, A., additional, Brandicourt, A., additional, Duboz, M.-A., additional, Fichtner, C., additional, Girard, L., additional, Gonnaud, F., additional, Haumont, D., additional, Hüppi, P., additional, Isaia, S., additional, Knezovic, N., additional, Legouais, S., additional, Mons, F., additional, Pelofy, V., additional, Picaud, J.-C., additional, Pierrat, V., additional, Renesme, L., additional, Sizun, J., additional, Souet, G., additional, Thiriez, G., additional, Truffert, P., additional, Zaoui, C., additional, and Zores, C., additional

Published
2016
Full Text
View/download PDF

27. The effects of maternal voice on pain during placement of peripherally inserted central catheter in neonates.

Author

Flours A, Mons F, Bedu A, Lauvray T, Blanquart AL, Woillard JB, Mowendabeka A, Guigonis V, and Ponthier L

Abstract

Background: Peripherally inserted central catheter (PICC) are a necessary procedure for preterm newborns care. Despite the use of analgesic treatments, its insertion can be painful. Our objective was to study the effect of maternal voice on pain during PICC insertion., Method: We conducted a pre post study for 2 years. Pain was compared between the two groups (with/without maternal presence) using a neonatal pain scale (FANS). Infection rate, procedure time, number of failures, mothers' anxiety and caregivers'anxiety were compared between the two groups., Results: Ninety neonates were eligible. Finally, 63 neonates were included. Thirty-four placements were realized without maternal voice (first period) and 29 with maternal voice (second period). Mean FANS during PICC placement was lower in the maternal voice group than in the control group (1.15 ± 1.27 vs. 1.41 ± 1.49, p  = 0.033). The FANS was also lower in the maternal voice group during the time of the first cutaneous effraction ( p  = 0.032). There was no significant difference between the two groups concerning the other outcomes., Conclusion: Maternal voice added to conventional care decreased acute pain during PICC insertion without increasing infection rate, number of failures or procedure time., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2024 Flours, Mons, Bedu, Lauvray, Blanquart, Woillard, Mowendabeka, Guigonis and Ponthier.)

Published
2024
Full Text
View/download PDF

28. Vaginal screening for group B streptococcus using PCR in pregnant women with unknown colonization status: Impact on newborn monitoring for early-onset sepsis.

Author

Blanquart AL, Garnier F, Lauvray T, Mazeau PC, Martinez S, Catalan C, Guigonis V, Bedu A, Mons F, and Ponthier L

Subjects
Humans, Female, Pregnancy, Infant, Newborn, Retrospective Studies, Adult, Carrier State diagnosis, Carrier State microbiology, Antibiotic Prophylaxis methods, Infectious Disease Transmission, Vertical prevention & control, Streptococcal Infections diagnosis, Streptococcal Infections drug therapy, Streptococcus agalactiae isolation & purification, Streptococcus agalactiae genetics, Vagina microbiology, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious microbiology, Polymerase Chain Reaction methods, Neonatal Sepsis diagnosis, Neonatal Sepsis microbiology
Abstract

Background: Early-onset neonatal sepsis represents a diagnostic challenge, as it is a cause of neonatal mortality and morbidity. Guidelines for the prevention of group B streptococcus (GBS) infection recommend that all pregnant women must be screened for GBS carriage at the end of pregnancy, with intrapartum antibiotic prophylaxis being provided for GBS carriers. If vaginal culture is not available, GBS polymerase chain reaction (GBS-PCR) is an alternative option for this type of screening. In our unit, GBS-PCR is performed when pregnant women present to the delivery room with ongoing labor and with no results of culture GBS screening available. The main objective of this study was to evaluate the impact of the results of GBS-PCR on monitoring modifications in newborns of mothers with unknown GBS status. The secondary objectives were to confirm the feasibility of a GBS-PCR-based screening method in everyday practice and to evaluate the impact of GBS-PCR results on the modification of intrapartum antibiotic therapy in pregnant women., Method: A retrospective, single-center, observational study was conducted for 1 year. For dyads with GBS-PCR performed, changes concerning intrapartum antibiotic therapy and the newborn's monitoring were recorded. The feasibility of the method was evaluated by the delay between the GBS-PCR realization and the availability of the result; in addition, the number of GBS-PCR tests that could not be realized were collected., Results: Overall, 60 GBS-PCR samples were tested for 60 pregnant women. Results were obtained for all samples, and the median duration to obtaining the GBS-PCR results was 70 min (60.8-87.2). These results were positive for 11 (18.3 %) women and led to monitoring modifications for two infants. In total, 27 pregnant women (45 %) had modifications in their antibiotic therapy due to the GBS-PCR results., Conclusion: GBS-PCR was quickly available and the results led to changes in maternal antibiotic prophylaxis and in the monitoring level of the newborns., Competing Interests: Conflict of interest None., (Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)

Published
2024
Full Text
View/download PDF

29. Distribution of proteinuria- and albuminuria-to-creatinine ratios in preterm newborns.

Author

Ponthier L, Trigolet M, Chianea T, Mons F, Yardin C, Guigonis V, and El Hamel C

Subjects
Albumins, Creatinine urine, Humans, Infant, Newborn, Prospective Studies, Albuminuria diagnosis, Albuminuria epidemiology, Infant, Premature, Kidney Diseases diagnosis, Kidney Diseases epidemiology, Proteinuria diagnosis, Proteinuria epidemiology
Abstract

Background: Urine protein assessment is important when glomerular disease or injury is suspected. Normal values of proteinuria already published for preterm newborns suffer from limitation, with small cohorts of patients. This prospective study was conducted to update the urine total protein- and albumin-to-creatinine ratio values., Methods: Urine samples were collected from 231 preterm newborns within the first 48 h (D0-1) and/or between 72-120 h of life (D3-4). Total protein, albumin, and creatinine were measured, their distribution and upper-limit values determined., Results: At D0-1 and D3-4, respectively, the median for the total protein-to-creatinine ratio were 80 and 107 mg/mmol (upper-limit values 223 and 289 mg/mmol) in the whole studied population, 149 and 214 mg/mmol in children born before 29 weeks of gestational age, 108 and 130 mg/mmol in those born between 29 and 33 weeks, and 61 and 93 mg/mmol in those born after 33 weeks. For the albumin-to-creatinine ratio, the median were 12 and 17 mg/mmol (upper-limit values 65 and 62 mg/mmol) in the whole studied population, 22 and 50 mg/mmol in children born before 29 weeks, 21 mg/mmol in those born between 29 and 33 weeks, and 8 and 12 mg/mmol in those born after 33 weeks. The use of nephrotoxic drugs and mechanical ventilation seems to influence proteinuria and albuminuria values., Conclusions: We report distribution of proteinuria- and albuminuria-to-creatinine in preterm newborns, including the upper-limit values. These values should be taken into account in the detection and diagnosis of glomerular disease and/or injury in daily clinical practice. Graphical abstract.

Published
2021
Full Text
View/download PDF

30. French neonatal society position paper stresses the importance of an early family-centred approach to discharging preterm infants from hospital.

Author

Pladys P, Zaoui C, Girard L, Mons F, Reynaud A, and Casper C

Subjects
Hospitals, Humans, Infant, Infant, Newborn, Intensive Care Units, Neonatal, Parents, Infant, Premature, Patient Discharge
Abstract

Aim: The families of hospitalised preterm infants risk depression and post-traumatic stress and the preterm infants risk re-hospitalisation. The French neonatal society's aim was to review the literature on how the transition from hospital to home could limit these risks and to produce a position paper., Methods: A systematic literature review was performed covering 1 January 2000 to 1 January 2018, and multidisciplinary experts examined the scientific evidence., Results: We identified 939 English and French papers and 169 are quoted in the position paper. Most studies stressed the importance of early, personalised and progressive involvement of the family. Healthcare staff and families should assess discharge preparations jointly. This evaluation should assess the capacities of the newborn infant, with regard to its physiological maturity. It should also assess the family's ability to supply the medical, psychological and social assistance required before and after discharge. There should be a structured follow-up process that includes effective communication, various tools, interventions, networks, health and social professionals., Conclusion: Discharge preparations may improve the transition from hospital to home and the outcomes for the parents and newborn preterm infant. This early family-centred approach should be structured, coordinated and based on individual needs and circumstances., (© 2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

32. Neonatal Outbreak of Methicillin-Resistant Staphylococcus aureus Clone Geraldine: A Bundle of Measures to Halt Transmission.

Author

Couvé-Deacon E, Mons F, Garnier F, Leduc P, Ponthier L, Domelier M, Tristan A, Ploy MC, and Pestourie N

Subjects
Cross Infection microbiology, France epidemiology, Humans, Infant, Infant, Newborn, Intensive Care Units, Neonatal, Methicillin Resistance, Methicillin-Resistant Staphylococcus aureus drug effects, Methicillin-Resistant Staphylococcus aureus genetics, Staphylococcal Infections transmission, Cross Infection epidemiology, Disease Outbreaks, Infection Control, Methicillin-Resistant Staphylococcus aureus isolation & purification, Staphylococcal Infections epidemiology
Published
2017
Full Text
View/download PDF

33. Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in France in 2011: results of the EPIPAGE-2 cohort study.

Author

Ancel PY, Goffinet F, Kuhn P, Langer B, Matis J, Hernandorena X, Chabanier P, Joly-Pedespan L, Lecomte B, Vendittelli F, Dreyfus M, Guillois B, Burguet A, Sagot P, Sizun J, Beuchée A, Rouget F, Favreau A, Saliba E, Bednarek N, Morville P, Thiriez G, Marpeau L, Marret S, Kayem G, Durrmeyer X, Granier M, Baud O, Jarreau PH, Mitanchez D, Boileau P, Boulot P, Cambonie G, Daudé H, Bédu A, Mons F, Fresson J, Vieux R, Alberge C, Arnaud C, Vayssière C, Truffert P, Pierrat V, Subtil D, D'Ercole C, Gire C, Simeoni U, Bongain A, Sentilhes L, Rozé JC, Gondry J, Leke A, Deiber M, Claris O, Picaud JC, Ego A, Debillon T, Poulichet A, Coliné E, Favre A, Fléchelles O, Samperiz S, Ramful D, Branger B, Benhammou V, Foix-L'Hélias L, Marchand-Martin L, and Kaminski M

Subjects
Cohort Studies, Female, France, Gestational Age, Humans, Infant, Infant, Newborn, Intensive Care, Neonatal, Morbidity, Pregnancy, Prospective Studies, Survival Rate, Infant Mortality, Infant, Premature, Infant, Premature, Diseases mortality, Premature Birth mortality
Abstract

Importance: Up-to-date estimates of the health outcomes of preterm children are needed for assessing perinatal care, informing parents, making decisions about care, and providing evidence for clinical guidelines., Objectives: To determine survival and neonatal morbidity of infants born from 22 through 34 completed weeks' gestation in France in 2011 and compare these outcomes with a comparable cohort in 1997., Design, Setting, and Participants: The EPIPAGE-2 study is a national, prospective, population-based cohort study conducted in all maternity and neonatal units in France in 2011. A total of 2205 births (stillbirths and live births) and terminations of pregnancy at 22 through 26 weeks' gestation, 3257 at 27 through 31 weeks, and 1234 at 32 through 34 weeks were studied. Cohort data were collected from January 1 through December 31, 1997, and from March 28 through December 31, 2011. Analyses for 1997 were run for the entire year and then separately for April to December; the rates for survival and morbidities did not differ. Data are therefore presented for the whole year in 1997 and the 8-month and 6-month periods in 2011., Main Outcomes and Measures: Survival to discharge and survival without any of the following adverse outcomes: grade III or IV intraventricular hemorrhage, cystic periventricular leukomalacia, severe bronchopulmonary dysplasia, retinopathy of prematurity (stage 3 or higher), or necrotizing enterocolitis (stages 2-3)., Results: A total of 0.7% of infants born before 24 weeks' gestation survived to discharge: 31.2% of those born at 24 weeks, 59.1% at 25 weeks, and 75.3% at 26 weeks. Survival rates were 93.6% at 27 through 31 weeks and 98.9% at 32 through 34 weeks. Infants discharged home without severe neonatal morbidity represented 0% at 23 weeks, 11.6% at 24 weeks, 30.0% at 25 weeks, 47.5% at 26 weeks, 81.3% at 27 through 31 weeks, and 96.8% at 32 through 34 weeks. Compared with 1997, the proportion of infants surviving without severe morbidity in 2011 increased by 14.4% (P < .001) at 25 through 29 weeks and 6% (P < .001) at 30 through 31 weeks but did not change appreciably for those born at less than 25 weeks. The rates of antenatal corticosteroid use, induced preterm deliveries, cesarean deliveries, and surfactant use increased significantly in all gestational-age groups, except at 22 through 23 weeks., Conclusions and Relevance: The substantial improvement in survival in France for newborns born at 25 through 31 weeks' gestation was accompanied by an important reduction in severe morbidity, but survival remained rare before 25 weeks. Although improvement in survival at extremely low gestational age may be possible, its effect on long-term outcomes requires further studies. The long-term results of the EPIPAGE-2 study will be informative in this regard.

Published
2015
Full Text
View/download PDF

34. [Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France].

Author

Pinquier D, Gouyon JB, Fauroux B, Mons F, Vicaut E, Bendjenana H, Rouffiac E, Marret S, and Aujard Y

Subjects
Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antiviral Agents adverse effects, Bronchopulmonary Dysplasia complications, Female, Follow-Up Studies, France, Gestational Age, Heart Defects, Congenital complications, Hospitalization statistics & numerical data, Humans, Infant, Infant, Low Birth Weight, Infant, Newborn, Infant, Premature, Diseases immunology, Male, Multicenter Studies as Topic, Palivizumab, Prospective Studies, Respiratory Syncytial Virus Infections immunology, Retrospective Studies, Risk Factors, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antiviral Agents therapeutic use, Disease Outbreaks, Infant, Premature, Diseases prevention & control, Respiratory Syncytial Virus Infections prevention & control
Abstract

Background: Infants treated have been followed for one year in order to assess conditions of use of palivizumab, safety, tolerability, and its impact on respiratory syncytial virus (RSV) hospitalisation rate., Patients and Methods: Patients who received palivizumab during the epidemic season 2005-2006 were eligible. Follow-up was carried out 12 months after initiation of prophylaxis., Results: Sixty-four neonatal level II and III centers, pulmonary and cardiology units enrolled 1420 children. Mean follow-up was 10.9+/-0.2 months, mean gestational age (GA) 30+/-4 weeks and mean age at the start of prophylaxis was 5 months. Median number of injections was 5 and mean time interval between 2 consecutive injections was 30+/-6 days. Treatment was prescribed in accordance with the marketing authorisation indications (MA) for 84% of patients. For preterm infants born before 35 SA and less than 6 months of age, 60% was born before 33 SA and without BDP. The global readmission rate (for more than 24h) for documented RSV infection during the period of protection by palivizumab was 2.7% (37 in 1371) for all treated children: respectively 2% [IC(95%)=1.3-3.2], 2.7% [IC(95%)=0.7-4.7] and 3.7% [IC(95%)=0.8-6.6] for preterm infants less than 6 months of age, preterm from 6 to 24 months of age and for children with congenital cardiopathy. Palivizumab safety and tolerability were good., Conclusion: Evaluation of palivizumab prophylaxis in clinical practice confirms the clinical characteristics of treated infants, outlines their evolution and confirms safety of treatment. MA were generally well observed and a registry could be usefull to track the impact of the treatment out of MA.

Published
2009
Full Text
View/download PDF

35. [Neuromotor outcome at 2 years of age in children born between 27 and 32 GW with periventricular leukomalacia. Retrospective 11-year study at the Rouen University Hospital].

Author

Gobalakichenane P, Labarre A, Mons F, Galène-Gromez S, Laudenbach V, and Marret S

Subjects
Brain Damage, Chronic epidemiology, Cerebral Palsy epidemiology, Child, Preschool, Cross-Sectional Studies, Disability Evaluation, Echoencephalography, Female, Follow-Up Studies, France, Humans, Incidence, Infant, Infant, Newborn, Infant, Premature, Diseases epidemiology, Leukomalacia, Periventricular epidemiology, Pregnancy, Pregnancy Trimester, Third, Prognosis, Retrospective Studies, Risk Assessment, Brain Damage, Chronic diagnosis, Cerebral Palsy diagnosis, Infant, Low Birth Weight, Infant, Premature, Diseases diagnosis, Leukomalacia, Periventricular diagnosis
Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results